



GAU1646
ATTORNEY'S DOCKET NO. R0547/7007 (ERG/KA)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: James K. Liao, et al.
Serial No. 09/273,445
Filed: March 19, 1999
For: UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE
SYNTHASE BY HMG-COA REDUCTASE INHIBITORS
Examiner: not yet assigned
Art Unit: 1646

RECEIVED

DEC 8 2000

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the 30th day of November, 2000.

Konstantinos Andrikopoulos
Konstantinos Andrikopoulos

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- ☒ Response to Restriction Requirement
- ☒ Return Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617)720-3500, Boston, Massachusetts.

No fee is required. If any fee is determined to be due by the Examiner, the Examiner is authorized to charged the appropriate fee to the account of the undersigned, Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully Submitted,

Edward R. Gates, Reg. No.: 31,616
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617)720-3500

Attorney's Docket No.: R0547/7007
Date: November 30, 2000
x11/30/00



ATTORNEY'S DOCKET NO.: R0547/7007(ERG/KA)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: LIAO, James K.
Serial No.: 09/273,445
Filed: March 19, 1999
For: UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE
BY AGENTS THAT DISRUPT ACTIN CYTOSKELETAL ORGANIZATION
Examiner: not yet assigned
Art Unit: 1646

#9
5/19/00
12/26/00

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 30th day of November, 2000.

Konstantinos Andrikopoulos
Konstantinos Andrikopoulos

COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement (paper 8) mailed from the United States Patent and Trademark Office on October 30, 2000, Applicants elect Group I, drawn to "methods of use," and elect species (g) "a method for increasing blood flow" Claims 167-204, 213-216 (and not Claims 205-206 as designated by the Examiner in the Restriction Requirement), for further prosecution on the merits.

REMARKS

In the event that the elected species (g) claims are found allowable, Applicant's respectfully request that the examiner rejoin the non-elected claims of species (a) - (f) and (h) for further prosecution in this application.

Respectfully Submitted,

Edward R. Gates
Edward R. Gates, Reg. No.: 31,616
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617)720-3500

Attorney's Docket No.: R0547/7007
Date:
x11/30/00